{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:23:40Z","timestamp":1791296620773,"version":"4.1.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Randomized controlled trials have shown a reduction in platelet alloimmunization and refractoriness in patients with acute leukemia (AL) with the use of poststorage leukoreduction of blood products. Universal prestorage leukoreduction (ULR) of red cell and platelet products has been performed in Canada since August 1999. We conducted a retrospective analysis of 13 902 platelet transfusions in 617 patients undergoing chemotherapy (CT) for AL or stem cell transplantation (SCT) before (n = 315) and after (n = 302) the introduction of ULR. Alloimmunization was significantly reduced (19% to 7%, P &amp;lt; .001) in the post-ULR group. Alloimmune platelet refractoriness was similarly reduced (14% to 4%, P &amp;lt; .001). Fewer patients in the post-ULR group received HLA-matched platelets (14% vs 5%, P &amp;lt; .001). Alloimmunization and alloimmune refractoriness in the 318 patients who were previously pregnant and\/or transfused were also reduced after ULR (P = .023 and P = .005, respectively). In a Cox regression model, the 3 independent factors that predicted for alloimmune refractoriness were nonleukoreduced blood products (relative risk [RR], 2.2 [95% CI, 1.2-4.3]), a history of pregnancy and\/or transfusion (RR, 2.3 [95% CI, 1.3-4.2]), and receipt of 13 or more platelet transfusions (RR, 6.0 [95% CI, 2.4-15.3]). In conclusion, ULR reduces alloimmunization, refractoriness, and requirements for HLA-matched platelets when applied as routine transfusion practice to patients receiving CT or SCT.<\/jats:p>","DOI":"10.1182\/blood-2003-03-0940","type":"journal-article","created":{"date-parts":[[2003,9,8]],"date-time":"2003-09-08T22:21:21Z","timestamp":1063059681000},"page":"333-339","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":129,"title":["Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness"],"prefix":"10.1182","volume":"103","author":[{"given":"Matthew D.","family":"Seftel","sequence":"first","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gershon H.","family":"Growe","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Petraszko","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Barrett","family":"Benny","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Le","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yong","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Spinelli","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Sutherland","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tsang","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Hogge","sequence":"additional","affiliation":[{"name":"From the Leukemia\/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222445627700_REF1","doi-asserted-by":"crossref","unstructured":"Schiffer C, Dutcher JP, Aisner A, Hogge D, Wiernik PH, Reilly JP. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood. 1983;62: 815-820.","DOI":"10.1182\/blood.V62.4.815.815"},{"key":"2020021222445627700_REF2","doi-asserted-by":"crossref","unstructured":"Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood. 1988;72: 964-969.","DOI":"10.1182\/blood.V72.3.964.bloodjournal723964"},{"key":"2020021222445627700_REF3","doi-asserted-by":"crossref","unstructured":"Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood. 1988;71: 1402-1407.","DOI":"10.1182\/blood.V71.5.1402.1402"},{"key":"2020021222445627700_REF4","doi-asserted-by":"crossref","unstructured":"Oksanen K, Kekomaki R, Ruutu T, Koskimies S, Myllyla G. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components\u2014a randomized trial. Transfusion. 1991;31: 588-594.","DOI":"10.1046\/j.1537-2995.1991.31791368333.x"},{"key":"2020021222445627700_REF5","doi-asserted-by":"crossref","unstructured":"Van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood. 1991;77: 201-205.","DOI":"10.1182\/blood.V77.1.201.201"},{"key":"2020021222445627700_REF6","doi-asserted-by":"crossref","unstructured":"Williamson LM, Wimperis JZ, Williamson P, et al. Bedside filtration of blood products in the prevention of HLA alloimmunization\u2014a prospective, randomized study. Blood. 1994;83: 3028-3035.","DOI":"10.1182\/blood.V83.10.3028.3028"},{"key":"2020021222445627700_REF7","doi-asserted-by":"crossref","unstructured":"The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. New Eng J Med. 1997;337: 1861-1869.","DOI":"10.1056\/NEJM199712253372601"},{"key":"2020021222445627700_REF8","doi-asserted-by":"crossref","unstructured":"Sintnicolaas K, Van Marwijk Kooy M, van Prooijen HC, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood. 1995;85: 824-828.","DOI":"10.1182\/blood.V85.3.824.bloodjournal853824"},{"key":"2020021222445627700_REF9","unstructured":"Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol. 1981;9: 77-83."},{"key":"2020021222445627700_REF10","doi-asserted-by":"crossref","unstructured":"Murphy MF, Metcalfe P, Thomas H, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol. 1986;62: 529-534.","DOI":"10.1111\/j.1365-2141.1986.tb02965.x"},{"key":"2020021222445627700_REF11","doi-asserted-by":"crossref","unstructured":"Schiffer CA. Diagnosis and management of refractoriness to platelet transfusion. Blood Rev. 2001;15: 175-180.","DOI":"10.1054\/blre.2001.0164"},{"key":"2020021222445627700_REF12","doi-asserted-by":"crossref","unstructured":"Hogge DE, McConnell M, Jacobson C, Sutherland HJ, Benny WB, Massing BG. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients. Transfusion. 1995;35: 645-652.","DOI":"10.1046\/j.1537-2995.1995.35895357895.x"},{"key":"2020021222445627700_REF13","doi-asserted-by":"crossref","unstructured":"Welsh KI, Burgos H, Batchelor JR. The immune response to allogeneic rat platelets; Ag-B antigens in matrix form lacking Ia. Eur J Immunol. 1977;7: 267-272.","DOI":"10.1002\/eji.1830070505"},{"key":"2020021222445627700_REF14","doi-asserted-by":"crossref","unstructured":"Kekomaki S, Volin L, Koistinen P, et al. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia. Eur J Haematol. 1998;60: 112-118.","DOI":"10.1111\/j.1600-0609.1998.tb01007.x"},{"key":"2020021222445627700_REF15","doi-asserted-by":"crossref","unstructured":"Vamvakas EC. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med. 1998;12: 258-270.","DOI":"10.1016\/S0887-7963(98)80002-3"},{"key":"2020021222445627700_REF16","unstructured":"Muller-Steimhardt M, Schlenke P, Wagner T, Kluter H. Transfusion of platelet concentrates from pooled buffy-coats: comparison of bedside vs. prestorage leukofiltration. Transfus Med. 2000;10: 59-65."},{"key":"2020021222445627700_REF17","doi-asserted-by":"crossref","unstructured":"Novotny VM, van Doorn R, Witvliet MD, Claas FH, Brand A. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood. 1995;85: 1736-1741.","DOI":"10.1182\/blood.V85.7.1736.bloodjournal8571736"},{"key":"2020021222445627700_REF18","doi-asserted-by":"crossref","unstructured":"Blajchman MA, Bardossy L, Carmen RA, Goldman M, Heddle NM, Singal DP. An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion. Blood. 1992;79: 1371-1375.","DOI":"10.1182\/blood.V79.5.1371.1371"},{"key":"2020021222445627700_REF19","doi-asserted-by":"crossref","unstructured":"Kao KJ, Mickel M, Braine HG, et al. White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial: the Trap Study Group. Transfusion. 1995;35: 13-19.","DOI":"10.1046\/j.1537-2995.1995.35195090653.x"},{"key":"2020021222445627700_REF20","doi-asserted-by":"crossref","unstructured":"Popovsky MA. Quality of blood components filtered before storage and at the bedside: implications for transfusion practice. Transfusion. 1996;36: 470-474.","DOI":"10.1046\/j.1537-2995.1996.36596282594.x"},{"key":"2020021222445627700_REF21","unstructured":"Gibis B, Baladi JF. Leukoreduction: the techniques used, their effectiveness and costs. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1998."},{"key":"2020021222445627700_REF22","doi-asserted-by":"crossref","unstructured":"Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion. 2001;41: 691-712.","DOI":"10.1046\/j.1537-2995.2001.41050691.x"},{"key":"2020021222445627700_REF23","doi-asserted-by":"crossref","unstructured":"Goodnough LT. The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion. 2000;40: 1522-1527.","DOI":"10.1046\/j.1537-2995.2000.40121522.x"},{"key":"2020021222445627700_REF24","doi-asserted-by":"crossref","unstructured":"Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997;337: 1870-1875.","DOI":"10.1056\/NEJM199712253372602"},{"key":"2020021222445627700_REF25","doi-asserted-by":"crossref","unstructured":"Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 x 109\/L trigger for prophylactic platelet transfusions compared with the traditional 20 \u00d7 109\/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91: 3601-3606.","DOI":"10.1182\/blood.V91.10.3601"},{"key":"2020021222445627700_REF26","doi-asserted-by":"crossref","unstructured":"Duquesnoy RJ, Filip DJ, Rodey GE, Rimm AA, Aster RH. Successful transfusion of platelets \u201cmismatched\u201d for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol. 1977;2: 219-226.","DOI":"10.1002\/ajh.2830020303"},{"key":"2020021222445627700_REF27","doi-asserted-by":"crossref","unstructured":"Brand A, Van Leeuwen A, Eernisse JG, van Rood JJ. Platelet transfusion therapy: optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Blood. 1978;51: 781-788.","DOI":"10.1182\/blood.V51.5.781.781"},{"key":"2020021222445627700_REF28","doi-asserted-by":"crossref","unstructured":"Mittal KK, Mickey MR, Singal DP, Terasaki PI. Serotyping for homotransplantation: 18. refinement of microdroplet lymphocyte cytotoxicity test. Transplantation. 1968;6: 913-927.","DOI":"10.1097\/00007890-196811000-00006"},{"key":"2020021222445627700_REF29","doi-asserted-by":"crossref","unstructured":"Hogge DE, Dutcher JP, Aisner J, Schiffer CA. Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol. 1983;14: 363-369.","DOI":"10.1002\/ajh.2830140407"},{"key":"2020021222445627700_REF30","doi-asserted-by":"crossref","unstructured":"Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley; 1989.","DOI":"10.2307\/2531779"},{"key":"2020021222445627700_REF31","doi-asserted-by":"crossref","unstructured":"Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet. 1991;338: 1223-1226.","DOI":"10.1016\/0140-6736(91)92098-M"},{"key":"2020021222445627700_REF32","doi-asserted-by":"crossref","unstructured":"Vamvakas EC, Blajchman MA. Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion. Transfus Med Rev. 2000;14: 23-33.","DOI":"10.1016\/S0887-7963(00)80113-3"},{"key":"2020021222445627700_REF33","doi-asserted-by":"crossref","unstructured":"Engelfriet CP, Reesink HW, Pietersz RN, et al. Universal leucocyte-depletion of blood components: cell concentrates and plasma. Vox Sang. 2001;81: 56-77.","DOI":"10.1046\/j.1423-0410.2001.00043.x"},{"key":"2020021222445627700_REF34","doi-asserted-by":"crossref","unstructured":"Toor AA, Choo SY, Little JA. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant. 2000;26: 315-320.","DOI":"10.1038\/sj.bmt.1702490"},{"key":"2020021222445627700_REF35","doi-asserted-by":"crossref","unstructured":"Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19: 1519-1538.","DOI":"10.1200\/JCO.2001.19.5.1519"},{"key":"2020021222445627700_REF36","doi-asserted-by":"crossref","unstructured":"Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion. 1999;39: 231-238.","DOI":"10.1046\/j.1537-2995.1999.39399219278.x"},{"key":"2020021222445627700_REF37","doi-asserted-by":"crossref","unstructured":"Heddle NM, Klama LN, Griffith L, Roberts R, Shukla G, Kelton JG. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion. 1993;33: 794-797.","DOI":"10.1046\/j.1537-2995.1993.331094054613.x"},{"key":"2020021222445627700_REF38","unstructured":"Muir JC, Jacobson S, Herschel L, AuBuchon JP. Does prestorage leukocyte reduction of blood components reduce the risk of febrile reactions in sensitized patients [abstract]? Blood.1994;84: 464a."},{"key":"2020021222445627700_REF39","doi-asserted-by":"crossref","unstructured":"Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion. 2001;41: 997-1000.","DOI":"10.1046\/j.1537-2995.2001.41080997.x"},{"key":"2020021222445627700_REF40","doi-asserted-by":"crossref","unstructured":"Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion. 2002;42: 556-566.","DOI":"10.1046\/j.1537-2995.2002.00094.x"},{"key":"2020021222445627700_REF41","doi-asserted-by":"crossref","unstructured":"Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86: 3598-3603.","DOI":"10.1182\/blood.V86.9.3598.bloodjournal8693598"},{"key":"2020021222445627700_REF42","doi-asserted-by":"crossref","unstructured":"van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation. 1998;97: 562-568.","DOI":"10.1161\/01.CIR.97.6.562"},{"key":"2020021222445627700_REF43","doi-asserted-by":"crossref","unstructured":"Ratko TA, Cummings JP, Oberman HA, et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion. 2001;41: 1310-1319.","DOI":"10.1046\/j.1537-2995.2001.41101310.x"},{"key":"2020021222445627700_REF44","doi-asserted-by":"crossref","unstructured":"Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101: 4195-4200.","DOI":"10.1182\/blood-2002-10-3143"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/1\/333\/1693992\/zh800104000333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/1\/333\/1693992\/zh800104000333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T22:45:17Z","timestamp":1581547517000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/1\/333\/17582\/Universal-prestorage-leukoreduction-in-Canada"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-03-0940","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}